Small molecule (PROTAC degrader) · Degrader of BCL6 · developed by Arvinas
Zaloblideg is an orally bioavailable PROTAC degrader that targets BCL6 for proteasome-mediated degradation. It binds BCL6 on tumor cells while recruiting E3 ubiquitin ligase, inducing BCL6 degradation and inhibiting downstream survival pathways. It is studied in relapsed/refractory mature B-cell non-Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06393738 | Phase 1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Recruiting | ARVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Updated Oct 3, 2026. Something wrong or missing? Report it on the ARVN page.
See ARVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARVN catalysts and pipeline →